An oligopeptide and its application in the preparation of products that improve vascular endothelial dysfunction.

By developing the oligopeptide AIPYL, multi-target synergistic regulation was achieved, which solved the problems of limited efficacy and large side effects in improving vascular endothelial dysfunction in existing technologies, and provided a highly efficient and safe treatment strategy for vascular endothelial dysfunction.

CN120737147BActive Publication Date: 2026-11-10完美(广东)日用品有限公司 +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510812956.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-06-18
Publication Date
2026-11-10
Estimated Expiration
2045-06-18

AI Technical Summary

Technical Problem

Existing technologies have limited efficacy and significant side effects in improving vascular endothelial dysfunction. In particular, the use of captopril-like drugs may lead to serious side effects such as hypotension. The active peptide in CN 117229355 A has adverse effects on cardiovascular function at high doses.

Method used

An oligopeptide, AIPYL, with the amino acid sequence Ala-Ile-Pro-Tyr-Leu, was developed. Through multi-target synergistic regulation, it inhibits ACE activity, promotes NO production, inhibits ET-1 production, enhances the antioxidant defense system, and reduces the expression of inflammatory factors. It can be used to prepare products that improve vascular endothelial dysfunction.

Benefits of technology

The oligopeptide AIPYL significantly improves vascular endothelial dysfunction, promotes NO production, inhibits ET-1, enhances antioxidant capacity, and reduces inflammatory response and adhesion factor expression, demonstrating high efficacy and no toxic side effects as a therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120737147B_ABST
    Figure CN120737147B_ABST
Patent Text Reader

Abstract

This invention relates to an oligopeptide and its application in the preparation of products for improving vascular endothelial dysfunction, belonging to the field of biotechnology. The invention provides an oligopeptide with the amino acid sequence Ala-Ile-Pro-Tyr-Leu. The oligopeptide AIPYL provided by this invention has significant innovation and advantages in improving vascular endothelial cell dysfunction. Through multi-target synergistic regulation, including inhibiting ACE activity, promoting NO production, inhibiting ET-1 production, enhancing the antioxidant defense system, reducing inflammatory factors, and reducing adhesion factor expression, it exhibits comprehensive and effective therapeutic potential. Compared with existing technologies, the AIPYL peptide not only has higher activity and efficiency but also has no toxic side effects, providing a new potential strategy for the treatment of vascular endothelial dysfunction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and more particularly to an oligopeptide and its application in the preparation of products that improve vascular endothelial dysfunction. Background Technology

[0002] Vascular endothelial cells, as a single layer of cells in the blood vessel wall, play a vital role in maintaining vascular homeostasis and health. They ensure the normal functioning of the vascular system by regulating vascular permeability, controlling vasoconstriction and vasodilation, maintaining vascular integrity, and participating in blood anticoagulation and coagulation processes. When vascular endothelial cells fail to function properly, endothelial dysfunction occurs. This dysfunction is the initial stage of cardiovascular disease development and can lead to various diseases such as hypertension, diabetes, atherosclerosis, and heart failure.

[0003] Endothelial dysfunction is a crucial pathological basis for various cardiovascular diseases, and its mechanisms involve an imbalance between oxidative stress and multiple signaling pathways. Under pathological conditions, angiotensin-converting enzyme (ACE) activity is abnormally elevated, catalyzing increased angiotensin II (Ang II) production. Ang II triggers a burst of NADPH oxidase (NOX)-dependent reactive oxygen species (ROS) by activating the angiotensin II type 1 receptor (AT1R). Simultaneously, the activity of antioxidant enzymes (such as catalase CAT and glutathione GSH) decreases, exacerbating oxidative damage and leading to the accumulation of malondialdehyde (MDA), the end product of lipid peroxidation. ROS uncouples endothelial nitric oxide synthase (eNOS) by consuming tetrahydrobiopterin (BH4), inhibiting nitric oxide (NO) synthesis and promoting the synthesis and release of endothelin-1 (ET-1). Decreased NO secretion is a key marker of endothelial dysfunction, not only weakening its mediated vasodilation and anti-inflammatory functions but also promoting monocyte adhesion and inflammatory infiltration by reducing the inhibition of vascular cell adhesion molecule-1 (VCAM-1), further exacerbating endothelial damage. Therefore, targeting and inhibiting ACE activity, blocking AT1R signaling, restoring NO homeostasis, reducing ET-1 secretion, and enhancing the antioxidant defense system have become key strategies for improving endothelial dysfunction. However, current clinical interventions are limited, mainly relying on ACE inhibitors such as captopril and plant-derived bioactive peptides.

[0004] Captopril is an angiotensin-converting enzyme inhibitor. Although it can improve vascular endothelial dysfunction, it is often accompanied by adverse reactions such as cough, gastrointestinal problems, and hypotension, and even serious side effects such as kidney damage and hyperkalemia. CN 117229355 A describes an active peptide derived from pumpkin seed cake and its preparation method and application. Although the active peptide monomer prepared by this patented technology has a good ACE inhibitory effect, it reduces the production of ET-1 in EA.hy926 cells by more than 90% at an extremely low dose of 100 μg / mL. The significant reduction in ET-1 can also have adverse effects on cardiovascular function, leading to the development of a series of diseases (such as causing circulatory symptoms such as hypotension), posing certain safety risks.

[0005] Therefore, there is an urgent need to develop novel drugs with multi-target synergistic regulation for use in the preparation of products that improve vascular endothelial dysfunction. Summary of the Invention

[0006] The purpose of this invention is to overcome the shortcomings of the prior art and provide an oligopeptide that improves vascular endothelial dysfunction and its application in the preparation of products that improve vascular endothelial dysfunction.

[0007] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides an oligopeptide, wherein the amino acid sequence of the oligopeptide is Ala-Ile-Pro-Tyr-Leu.

[0008] The oligopeptide of this invention has the amino acid sequence Ala-Ile-Pro-Tyr-Leu, and experiments have confirmed that it has the activity of inhibiting angiotensin-converting enzyme (ACE).

[0009] Secondly, the present invention provides the application of oligopeptides in the preparation of angiotensin-converting enzyme inhibitors.

[0010] Thirdly, the present invention provides an angiotensin-converting enzyme inhibitor, wherein the inhibitor comprises the above-mentioned oligopeptide.

[0011] Fourthly, this invention provides the application of the above-mentioned oligopeptide in the preparation of products that improve vascular endothelial dysfunction. This invention experimentally demonstrates that the oligopeptide AIPYL has the following effects: (1) It promotes the production of NO factor by vascular endothelial cells, which helps to dilate blood vessels and relieve endothelial dysfunction.

[0012] (2) The effect of inhibiting the production of endothelin ET-1. ET-1 is a potent vasoconstrictor, and its overexpression is closely related to endothelial dysfunction.

[0013] (3) Excellent antioxidant effect, which can increase GSH content and CAT activity, while reducing MDA content, which helps to reduce oxidative stress damage and restore the normal function of endothelial cells.

[0014] (4) It significantly reduces the production of TNF-α, thereby alleviating vascular inflammatory response.

[0015] (5) It significantly reduces the expression levels of adhesion factors VCAM-1 and ICAM-1, thereby reducing leukocyte adhesion and migration to the vascular endothelium, thus alleviating the inflammatory response and endothelial damage. This effect helps restore the normal function of endothelial cells.

[0016] The oligopeptides of this invention exhibit comprehensive and effective therapeutic potential through multi-target synergistic regulation, including inhibiting ACE activity, promoting NO production, inhibiting ET-1 production, enhancing the antioxidant defense system, reducing inflammatory factors, and reducing adhesion factor expression.

[0017] As a preferred embodiment of the application described in this invention, the product for improving vascular endothelial dysfunction includes pharmaceuticals.

[0018] As a preferred embodiment of the application described in this invention, the oligopeptide can be compounded with ACE inhibitors and / or drugs that improve vascular endothelial dysfunction to form a product that improves vascular endothelial dysfunction.

[0019] Fifthly, the present invention provides an article having the effect of improving vascular endothelial dysfunction, comprising the above-mentioned oligopeptide.

[0020] In a preferred embodiment of the article of the present invention, the article further includes excipients.

[0021] In a preferred embodiment of the product described in this invention, the excipients include at least one of flavoring agents, thickeners, disintegrants, and fillers.

[0022] As a preferred embodiment of the product described in this invention, the dosage form of the composition for improving vascular endothelial cell dysfunction is at least one of capsules, pills, oral liquids, tablets, granules, powders, and injections.

[0023] Compared with the prior art, the beneficial effects of the present invention are as follows: The oligopeptide AIPYL provided in this invention has significant innovation and advantages in improving vascular endothelial cell dysfunction. Through multi-target synergistic regulation, including inhibiting ACE activity, promoting NO production, inhibiting ET-1 production, enhancing the antioxidant defense system, reducing inflammatory factors, and decreasing adhesion factor expression, it exhibits comprehensive and effective therapeutic potential. Compared with existing technologies, the AIPYL peptide not only has higher activity and efficiency but also has no toxic side effects, providing a new potential strategy for the treatment of vascular endothelial dysfunction. Attached Figure Description

[0024] Figure 1 This is the liquid chromatogram of the oligopeptide AIPYL in Example 1 of the present invention; Figure 2 This is the mass spectrum of the oligopeptide AIPYL in Example 1 of the present invention; Figure 3 The results of measuring the ACE inhibition rate of different concentrations of oligopeptide AIPYL in Example 1 of the present invention; Figure 4 The results of the determination of the effect of AIPYL on the production of NO factor by vascular endothelial cells in Example 2 of the present invention; Figure 5 The results of the determination of the effect of AIPYL on the production of ET-1 factor by vascular endothelial cells in Example 2 of the present invention; Figure 6 The results of measuring the effect of AIPYL on the antioxidant factors of vascular endothelial cells in Example 2 of the present invention are shown, where A is reduced glutathione, B is catalase, and C is malondialdehyde. Figure 7 The results of the determination of the effect of AIPYL on the production of inflammatory factors by vascular endothelial cells in Example 2 of the present invention; Figure 8 The results of measuring the effect of AIPYL on the expression of adhesion factors in vascular endothelial cells in Example 2 of the present invention are shown, where A is VCAM-1 and B is ICAM-1. In the above figures, symbols marked with "#", "##", or "###" indicate significant differences compared to the blank control group (P < 0.05, P < 0.01, or P < 0.001); symbols marked with "#" indicate significant differences compared to the blank control group. " "or" "" indicates a significant difference compared to the model group (P < 0.05, P < 0.01, or P < 0.001). In the above figure, a "-" on the horizontal axis indicates that the corresponding reagent was not added to the group, while a "+" indicates that the corresponding reagent was added to the group. Detailed Implementation

[0025] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0026] Unless otherwise specified, all other materials and reagents used in the examples are commercially available.

[0027] The techniques not described in detail in the following examples, comparative examples and effect examples are all commonly used techniques in the field. You can refer to "Molecular Biology Experiment Manual" (Ma Wenli, People's Military Medical Publishing House), "Molecular Biology Experiment (Second Edition)" (Zhejiang University Press), and "Cell Biology Experiment" (Yang Hongbing, Hou Lixia, Zhang Yuxi, Higher Education Press).

[0028] In the following examples and effect examples, "V" refers to valine (Val), "P" refers to proline (Pro), "G" refers to glycine (Gly), "H" refers to histidine (His), "R" refers to arginine (Arg), "K" refers to lysine (Lys), "I" refers to isoleucine (Ile), "F" refers to phenylalanine (Phe), "L" refers to leucine (Leu), "W" refers to tryptophan (Trp), "A" refers to alanine (Ala), "M" refers to methionine (Met), "C" refers to cysteine ​​(Cys), "N" refers to asparagine (Asn), "S" refers to serine (Ser), "Q" refers to glutamine (Gln), "Y" refers to tyrosine (Tyr), "D" refers to aspartic acid (Asp), "E" refers to glutamate (Glu), and "T" refers to threonine (Thr).

[0029] In the following examples and effect examples, AIPYL refers to an oligopeptide with the amino acid sequence SEQ ID NO.1.

[0030] HPLC-MS / MS detection parameters: A Waters 2695-ZQ2000 single quadrupole HPLC system (Waters, USA) was used for sample separation and detection. The column used was an ODS-SP (4.6×250mm×5μm) (Shimadzu, Japan). The mobile phase consisted of 0.1% (v / v) trifluoroacetic acid aqueous solution (A) and 0.1% (v / v) trifluoroacetic acid acetonitrile (B). The elution method was 0-25.00 min 10%~70% B, 25.01-30.00 min 100% B. The flow rate was 1 mL / min, the injection volume was 30 μL, and the column temperature was 40℃. The percentages of the mobile phase mentioned above mean volume percentage, which is the volume of mobile phase B divided by the total volume of mobile phase A and mobile phase B. Mass spectrometry detection method: scan period 0.1s, ESI ion source temperature 100℃, positive ion mode, spray voltage 3000V, scan range 300-1999Da.

[0031] In the following effect examples, the angiotensin-converting enzyme inhibitor activity assay kit was purchased from Beijing Solarbio Science & Technology Co., Ltd., catalog number BC5575; The NO detection kit was purchased from Shanghai Beyotime Biotechnology Co., Ltd., product number S0021S. The human endothelin (ET-1) ELISA kit was purchased from Shanghai Enzyme-Link Biotechnology Co., Ltd., catalog number ml025101; The reduced glutathione assay kit was purchased from Beijing Solarbio Technology Co., Ltd., product number BC1175. The catalase activity assay kit was purchased from Beijing Box Biotechnology Co., Ltd., product number AKAO003-1U; The lipid oxidation (malondialdehyde) activity assay kit was purchased from Shanghai Beyotime Biotechnology Co., Ltd., catalog number S0131S; The human tumor necrosis factor (TNF-α) ELISA kit was purchased from Shanghai Enzyme-Link Biotechnology Co., Ltd., catalog number ml064303; The reverse transcription kit, HiScript II Reverse Transcriptase, was purchased from Nanjing Novizan Biotechnology Co., Ltd., catalog number R201-01. The real-time PCR reagent was ChamQ Universal SYBR qPCR Master Mix, purchased from Nanjing Novizan Biotechnology Co., Ltd., catalog number Q711-02; RNA extraction was performed using TRIzol reagent, the source of which was not limited.

[0032] The internal control for qRT-PCR is GAPDH. The primer sequences for VCAM-1 and ICAM-1 are as follows: VCAM-1-F, 5'-TCTCATTGACTTGCAGCACCACAG-3'; VCAM-1-R, 5'-CCTCATTCGTCACCTTCCCATTCAG-3'; ICAM-1-F, 5′-GGTAGCAGCCGCAGTCATAATGG-3′; ICAM-1-R, 5'-GTGGCTTGTGTGTTCGGTTTCATG-3'.

[0033] Example 1 This embodiment provides an oligopeptide synthesized by solid-phase synthesis, commissioned to Nanjing Jietai Biotechnology Co., Ltd. The synthesized oligopeptide was characterized by HPLC-MS / MS, and the results are shown in Table 1. Figure 1-2The amino acid sequence of the oligopeptide is shown in SEQ ID NO.1.

[0034] Table 1. Identification results of oligopeptides As shown in Table 1 and Figure 1-2 As shown, an oligopeptide with a purity of up to 97.05% and an amino acid sequence of Ala-Ile-Pro-Tyr-Leu was successfully prepared using solid-phase synthesis, hereinafter referred to as AIPYL.

[0035] Example of effect 1 The efficacy of the oligopeptide AIPYL obtained in Example 1 was determined using the following specific method: Effects on angiotensin-converting enzyme (ACE).

[0036] A 1 mg / mL oligopeptide solution was prepared by reacting the oligopeptide AIPYL with a buffer reagent. This 1 mg / mL solution was then diluted to obtain oligopeptide solutions of 0.03125, 0.0625, 0.125, 0.25, and 0.5 mg / mL, respectively. These 0.03125–1.0 mg / mL solutions were used as test samples. The inhibitory effect of oligopeptide AIPYL on ACE was determined using the micro-method method as described in the instructions of the angiotensin-converting enzyme inhibitor activity assay kit. The results are shown in Table 2. Figure 3 .

[0037] Table 2. Effects of oligopeptide AIPYL on ACE inhibitory activity. As shown in Table 2 and Figure 3 As shown, the oligopeptide AIPYL has a very strong ACE inhibitory effect, with an ACE inhibition rate of 84.60% at a concentration of 1 mg / mL. This indicates that the oligopeptide AIPYL reduces the production of angiotensin II and the degradation of bradykinin by inhibiting ACE activity, thereby improving cardiovascular function.

[0038] Example 2 To evaluate the effect of the oligopeptide AIPYL obtained in Example 1 on vascular endothelial cells, the oligopeptide AIPYL was co-cultured with vascular endothelial cells and relevant indicators were detected. The specific protocol is as follows: In this case study, human umbilical vein endothelial cells (HUVECs) were used. The culture medium was DMEM containing 10% (v / v) fetal bovine serum, and the culture conditions were 37°C and 5% CO2.

[0039] 1. NO factor.

[0040] HUVEC cells were seeded in 6-well plates and cultured for 24 h. The culture medium was then removed, and each well was filled with either culture medium (control group), hydrogen peroxide solution (model group, prepared as 6 mM hydrogen peroxide solution using culture medium as solvent), or test sample solution (treatment group, prepared as 6 mM hydrogen peroxide solution and AIPYL solution using culture medium as solvent, with AIPYL concentrations of 50, 100, and 200 μM, respectively). After 24 h of incubation, NO levels were measured according to the NO kit instructions. The results are shown in Table 4. Figure 4 .

[0041] Table 4. Results of NO content detection in HUVEC cells of different treatment groups As shown in Table 4 and Figure 4 As shown, there was a highly significant difference between the blank control group and the model group, indicating that hydrogen peroxide successfully induced endothelial cell dysfunction. Hydrogen peroxide caused endothelial cells to produce excessive reactive oxygen species (ROS), which oxidized BH4, uncoupling and inactivating endothelial nitric oxide synthase (eNOS), thereby reducing NO production and leading to endothelial dysfunction. The oligopeptide AIPYL showed a significant promoting effect on NO production at three different doses (50, 100, and 200 μM), and this effect was clearly dose-dependent. In particular, the 100 μM and 200 μM doses of AIPYL significantly increased the production of NO factor, by 122.10% and 151.11% compared with the model group, respectively. These results indicate that the AIPYL peptide has a very strong ability to promote the production of NO factor by vascular endothelial cells, and its mechanism of action is related to the activation of endothelial nitric oxide synthase (eNOS) and the increase of NO bioavailability, thereby helping to dilate blood vessels and alleviate endothelial dysfunction.

[0042] 2. Endothelin-1 (ET-1) factor.

[0043] HUVEC cells were treated according to the above-described NO factor assay procedure, and the ET-1 factor level in the cells was detected using an ELISA kit. The results are shown in Table 5. Figure 5 .

[0044] Table 5. Results of ET-1 content detection in HUVEC cells from different treatment groups. As shown in Table 5 and Figure 5As shown, there was a highly significant difference between the blank control group and the model group, indicating that hydrogen peroxide successfully induced endothelial cell dysfunction, leading to a significant increase in endothelin-1 (ET-1) production. ET-1, as a potent vasoconstrictor, is often closely associated with endothelial dysfunction due to its overexpression. The oligopeptide AIPYL exhibited a highly significant inhibitory effect on ET-1 production at three different doses (50, 100, and 200 μM), and this effect was clearly dose-dependent. Specifically, 50 μM, 100 μM, and 200 μM doses of AIPYL significantly reduced ET-1 production by 20.17%, 24.33%, and 32.15%, respectively. Particularly at the 200 μM dose, there was no significant difference in ET-1 production compared to the blank control group, indicating that at this dose, the AIPYL peptide could restore the amount of ET-1 secreted by dysfunctional endothelial cells to normal levels. Increased ET-1 production is typically associated with oxidative stress and inflammatory responses, and the oligopeptide AIPYL, by inhibiting ET-1 production, may play a significant role in reducing oxidative stress, suppressing inflammatory responses, and improving vascular tone. This mechanism of action could help alleviate endothelial dysfunction and restore normal vascular physiological function.

[0045] 3. Antioxidant factors.

[0046] HUVEC cells were treated according to the above-described NO factor assay procedure. The levels of reduced glutathione (GSH), catalase (CAT), and malondialdehyde (MDA) were measured according to the kit instructions. The results are shown in Table 6. Figure 6 .

[0047] Table 6. Results of GSH, CAT, and MDA content detection in HUVEC cells of different treatment groups (x̅±SD) AIPYL peptides exhibit significant antioxidant effects in improving vascular endothelial cell dysfunction. (See Table 6 and...) Figure 6 As shown, the oligopeptide AIPYL significantly increased GSH content and CAT activity at three different doses (50, 100, and 200 μM), while significantly reducing MDA content, indicating that it has strong antioxidant capacity.

[0048] Specifically, the oligopeptide AIPYL significantly increased GSH levels by 19.18% and 29.33% at 100 μM and 200 μM doses, respectively, even exceeding the levels in the normal group. This indicates that AIPYL can effectively enhance the antioxidant capacity of cells and protect them from oxidative stress damage. Furthermore, AIPYL significantly increased CAT activity, especially at the 200 μM dose, where CAT levels increased by 237.89% relative to the model group, and activity recovered to the normal group level, further confirming its effectiveness in enhancing antioxidant enzyme activity. Simultaneously, AIPYL significantly reduced MDA levels, and this reduction was clearly dose-dependent. At the 200 μM dose, MDA levels almost recovered to the level of the blank control group, indicating that the AIPYL peptide can effectively inhibit lipid peroxidation and alleviate oxidative stress damage.

[0049] Oxidative stress is a key mechanism of endothelial dysfunction. Excessive reactive oxygen species (ROS) damage cell membranes and proteins, leading to endothelial dysfunction. The oligopeptide AIPYL helps restore normal endothelial cell function by enhancing cellular antioxidant capacity, inhibiting lipid peroxidation, and mitigating oxidative stress damage. These results demonstrate that the oligopeptide AIPYL possesses significant antioxidant effects and can effectively improve vascular endothelial cell dysfunction.

[0050] 4. Inflammatory factors.

[0051] HUVEC cells were seeded in 6-well plates and cultured for 24 h. The culture medium was then removed, and each well was filled with either culture medium (control group), angiotensin II (Ang II) solution (model group, prepared as 10 μM angiotensin II solution using culture medium as solvent), or test sample solution (treatment group, prepared as 10 μM Ang II solution and AIPYL solution using culture medium as solvent, with AIPYL concentrations of 50, 100, and 200 μM, respectively). After 24 h of incubation, TNF-α levels were measured according to the ELISA kit instructions. The results are shown in Table 7. Figure 7 .

[0052] Table 7. Results of TNF-α content detection in HUVEC cells from different treatment groups. As shown in Table 7 and Figure 7As shown, the oligopeptide AIPYL exhibits a significant effect in reducing the production of tumor necrosis factor-α (TNF-α) by vascular endothelial cells, thus demonstrating good efficacy in improving vascular endothelial cell dysfunction. Experimental data show that the AIPYL peptide significantly reduced TNF-α production at three different doses (50, 100, and 200 μM), and this reduction effect was clearly dose-dependent. 50 μM, 100 μM, and 200 μM doses of oligopeptide AIPYL significantly reduced TNF-α production by 22.67%, 29.34%, and 39.45%, respectively. Particularly at the 200 μM dose, TNF-α production recovered to the level of the blank control group, indicating that oligopeptide AIPYL can effectively inhibit the overexpression of TNF-α.

[0053] TNF-α, an important pro-inflammatory factor, plays a crucial role in endothelial dysfunction. Its overexpression exacerbates vascular inflammation and further damages endothelial cells. The oligopeptide AIPYL, by significantly reducing TNF-α production, may play an important role in alleviating vascular inflammation, inhibiting endothelial cell damage, and improving vascular tone.

[0054] 5. Adhesion factors.

[0055] HUVEC cells were treated according to the above-described procedure for the inflammatory factor assay. Total RNA was extracted from the cells, reverse transcribed, and then subjected to qRT-PCR. The adhesion factors measured included VCAM-1 and ICAM-1. The results are shown in [Figure number missing]. Figure 8 See Table 8.

[0056] Table 8. Results of relative expression of VCAM-1 and ICAM-1 in HUVEC cells from different treatment groups. like Figure 8 As shown in Table 8, the oligopeptide AIPYL reduced the mRNA expression levels of VCAM-1 and ICAM-1 at three different doses, with the reduction increasing with increasing concentration. The 200 μM dose showed a statistically significant difference compared to the model group, indicating that the AIPYL peptide effectively inhibited the overexpression of these adhesion molecules, VCAM-1 and ICAM-1. VCAM-1 and ICAM-1, as important inflammation-related adhesion molecules, play a crucial role in endothelial dysfunction. Their overexpression leads to leukocyte adhesion and migration to the vascular endothelium, exacerbating inflammatory responses and endothelial damage. The oligopeptide AIPYL, by significantly reducing the expression of VCAM-1 and ICAM-1, helps restore normal endothelial cell function.

[0057] In summary, the oligopeptide AIPYL of this invention exhibits significant ACE inhibition, promotes the production of NO factor by vascular endothelial cells, inhibits ET-1 production, reduces TNF-α factor production and adhesion factor expression levels, and also possesses excellent antioxidant activity. Through multi-target synergistic regulation, it demonstrates comprehensive and effective therapeutic potential. The oligopeptide exhibits higher activity and efficiency, and higher safety, providing a new potential strategy for the treatment of vascular endothelial dysfunction.

[0058] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. An oligopeptide, characterized in that, The amino acid sequence of the oligopeptide is Ala-Ile-Pro-Tyr-Leu.

2. An angiotensin-converting enzyme inhibitor, characterized in that, The inhibitor includes the oligopeptide as described in claim 1.

3. The use of the oligopeptide as described in claim 1 in the preparation of a product for improving vascular endothelial dysfunction; wherein the product for improving vascular endothelial dysfunction is a pharmaceutical product.

4. A product having the effect of improving vascular endothelial dysfunction, characterized in that, Includes the oligopeptides as described in claim 1.

5. The article of claim 4, characterized in that, The product also includes auxiliary materials.

6. The article of claim 5, characterized in that, The excipients include at least one of flavoring agents, thickeners, disintegrants, and fillers.

7. The article of claim 4, characterized in that, The dosage form of the product is at least one of capsules, pills, oral liquids, tablets, granules, powders, and injections.

Citation Information

Patent Citations

  • Active peptide from pumpkin seed cake and preparation method and application thereof

    CN117229355A